A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801)

Lin, GP; Liu, YL; Li, H; Chen, SY; Guo, YB

Guo, YB (corresponding author), Sun Yat Sen Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, Guangzhou 510080, Peoples R China.

CLINICAL LUNG CANCER, 2021; 22 (2): E157

Abstract

Background: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is now a standard treatment of previous......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索